Robert I. Field, PhD, JD
, a professor in the Dornsife School of Public Health and Kline School of Law, was quoted in a June 4 Washington Post
article about a team of Pfizer researchers who found its rheumatoid arthritis therapy drug could also potentially reduce the risk of Alzheimer’s disease. Field explained the procedures a company must go through to receive regulatory approval to use a drug for a completely different disease.